🔗 Share this article

Given that America proceeds with unprecedented adjustments to its immunization schedules, a particular individual appears unexpectedly: Høeg, a Danish American sports physician and epidemiologist who initially gained attention by casting doubt on Covid vaccines during the global health crisis and has concentrated on possible fatalities following COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Program

Agency leaders had intended to announce major changes to the pediatric vaccine schedule in December, bringing the US with the Danish vaccine program, it is understood – a significant shift that would place the US out of alignment with a large portion of the global community with no evidence for benefit. This reveal has been delayed until the coming year.

Rather than the top vaccines chief, Dr. Høeg is scheduled to present at the event. She was recently named interim head of the FDA’s CDER, the fifth person to lead the division this year.

A Shift at the FDA

The acting appointment could signify a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a increased emphasis upon reevaluating already-approved vaccines at the FDA.

Høeg has often pushed for discontinuing specific childhood shot schedules in the US so as to align more in line with the Danish model, a nation with comprehensive healthcare and a citizenry approximately the size of Wisconsin’s.

To date comments, she has kept her attention on immunizations – typically the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Background

The appointee has no obvious experience in medication creation, oversight or leadership, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the requisite experience” for leading the drug-regulation department, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in leading a major agency. She is not an expert in industry regulation.”

Previous commissioners of CBER would “understand regulatory frameworks and the research of drug development”, noted Dr. Janet Woodcock. “Objectively, she lacks the type of experience that previous people who ran the center have had.”

This division has an immense range of responsibilities at the agency, Woodcock stated.

“Many people just pays attention on the novel medication approvals, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and more, and each of these have to be looked after,” Dr. Woodcock said. “The area you neglect, that is the part that I always told people is going to bite you.”

Additionally, a significant leadership aspect to the job, which oversees in excess of 5,000 staff members. “It’s a enormous leadership role, if you do it right,” she added.

Official Statement and Contentious Initiatives

Regarding questions about Høeg’s fitness for the role and whether this selection indicates more teamwork among regulatory chiefs on immunizations, a press secretary stated that the “inquiries rely on inaccurate presumptions”.

“This background matches the functions of her job,” the official explained, noting the time Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's recently launched expedited review system, a disputed rapid drug-approval program that allegedly concerned her predecessors. “By what process are these medications being picked for this expedited pathway? Who takes the choices?” Dr. Howard asked. “There is a lot of secrecy going on at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards less stringent regulations of all drugs, except for immunizations.”

Documented Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a clearer, if concerning, past, critics said. She authored a analysis using non-validated public submissions to assess the rate of heart inflammation after Covid vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are riskier than they are.

Among her “wish list” for the incoming government featured changing rules for recently developed shots and discontinuing “non-essential” vaccines, she remarked post-election on a podcast. At the agency, Dr. Høeg has according to sources suggested preventing young men from obtaining Covid vaccinations.

“She’s an complete true believer who commences with her beliefs and works backwards to retrofit the science in a very disingenuous, dishonest fashion,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Høeg joined fellow contrarians, {like|